Clinical trial
A Phase 1, Multicenter, Open-label, Dose Finding Study of CC-96673 in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT04860466 is registered in ClinicalTrials.gov with Celgene as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Multicenter, Open-label, Dose Finding Study of CC-96673 in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma
- Lead sponsor
- Celgene
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- January 20, 2022
- Completion date
- July 31, 2024
- Enrollment
- 9 (actual)
- Sites
- 13
Conditions
As the registry lists them; a condition with its own page is linked.